| pubmed-article:11723278 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11723278 | lifeskim:mentions | umls-concept:C0034380 | lld:lifeskim |
| pubmed-article:11723278 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:11723278 | lifeskim:mentions | umls-concept:C0205329 | lld:lifeskim |
| pubmed-article:11723278 | lifeskim:mentions | umls-concept:C0175668 | lld:lifeskim |
| pubmed-article:11723278 | pubmed:issue | 10 | lld:pubmed |
| pubmed-article:11723278 | pubmed:dateCreated | 2001-11-27 | lld:pubmed |
| pubmed-article:11723278 | pubmed:abstractText | The recent randomized, controlled trial of interferon-beta1b (IFN-beta1b) in 718 patients with secondary progressive MS (SP-MS) demonstrated a significant effect on the development of disability as evaluated by the physician. Its effect on patient-reported health-related quality of life (HrQoL) is reported herein. | lld:pubmed |
| pubmed-article:11723278 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11723278 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11723278 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:11723278 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11723278 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11723278 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11723278 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11723278 | pubmed:month | Nov | lld:pubmed |
| pubmed-article:11723278 | pubmed:issn | 0028-3878 | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:HutchinsonMM | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:ThompsonA JAJ | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:FreemanJ AJA | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:DahlkeFF | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:FitzpatrickRR | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:KapposLL | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:PozzilliCC | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:BeckmannKK | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:MiltenburgerC... | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:PolmanCC | lld:pubmed |
| pubmed-article:11723278 | pubmed:author | pubmed-author:European... | lld:pubmed |
| pubmed-article:11723278 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11723278 | pubmed:day | 27 | lld:pubmed |
| pubmed-article:11723278 | pubmed:volume | 57 | lld:pubmed |
| pubmed-article:11723278 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11723278 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11723278 | pubmed:pagination | 1870-5 | lld:pubmed |
| pubmed-article:11723278 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:meshHeading | pubmed-meshheading:11723278... | lld:pubmed |
| pubmed-article:11723278 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11723278 | pubmed:articleTitle | Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. | lld:pubmed |
| pubmed-article:11723278 | pubmed:affiliation | Institute of Neurology, University College London, United Kingdom. | lld:pubmed |
| pubmed-article:11723278 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11723278 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11723278 | pubmed:publicationType | Randomized Controlled Trial | lld:pubmed |
| pubmed-article:11723278 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11723278 | pubmed:publicationType | Multicenter Study | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11723278 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11723278 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11723278 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11723278 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11723278 | lld:pubmed |
